Twelve week liraglutide or sitagliptin does not affect hepatic fat in type 2 diabetes: a randomised placebo-controlled trial

AIMS/HYPOTHESIS: Glucagon-like peptide (GLP)-1-based therapies have been suggested to improve hepatic steatosis. We assessed the effects of the GLP-1 receptor agonist liraglutide and the dipeptidyl peptidase (DPP)-4 inhibitor sitagliptin on hepatic steatosis and fibrosis in patients with type 2 diab...

Descripción completa

Detalles Bibliográficos
Autores principales: Smits, Mark M., Tonneijck, Lennart, Muskiet, Marcel H. A., Kramer, Mark H. H., Pouwels, Petra J. W., Pieters-van den Bos, Indra C., Hoekstra, Trynke, Diamant, Michaela, van Raalte, Daniël H., Cahen, Djuna L.
Formato: Online Artículo Texto
Lenguaje:English
Publicado: Springer Berlin Heidelberg 2016
Materias:
Short Communication
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC6518065/
https://www.ncbi.nlm.nih.gov/pubmed/27627981
http://dx.doi.org/10.1007/s00125-016-4100-7

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC6518065/
https://www.ncbi.nlm.nih.gov/pubmed/27627981
http://dx.doi.org/10.1007/s00125-016-4100-7

Ejemplares similares